Thor 707 sanofi
WebOct 29, 2024 · Sanofi is partnering with Merck to test its THOR-707 compound with Merck’s checkpoint inhibitor Keytruda (pembrolizumab) in solid tumors. THOR-707 is a non-alpha IL-2 candidate that is currently … WebDec 9, 2024 · THOR-707 could also work in combination with CD-38 targeting drugs such as isatuximab, as well as molecules that modulate effector T-cells and natural killer cells, Sanofi said. Image Richard Staines
Thor 707 sanofi
Did you know?
WebWhen Sanofi picked up biotech Synthorx for a cool $2.5 billion this month, it paid a rich premium to enter an increasingly competitive immunotherapy field. But in the face of stiff … WebApr 10, 2024 · On Friday, Sanofi rolled out a placeholder release for THOR-707 at the November data cutoff, and by March not much had changed in terms of efficacy.
WebDec 9, 2024 · Synthorx has said it believes THOR-707 can be safer and more effective. The company has an ongoing Phase 1/2 dose escalation and expansion trial, which started in the second quarter of 2024. Overall, the deal will bolster Sanofi's presence in oncology, which makes up 28 of the 85 ongoing clinical projects in the company's pipeline. WebApr 9, 2024 · Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2 Early clinical results are consistent with …
WebIn Cynomolgus monkey, subcutaneous dosing of THOR-809 demonstrated dose-dependent proliferation and activation of peripheral Tregs with no detectable proliferation of Teffs or … WebSanofi has struck a d Sanofi has struck a deal to buy Synthorx for $2.5 billion (€2.3 billion). The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi control of an IL-2 …
WebNov 19, 2024 · Its lead product candidate THOR-707, ... THOR-707 is in clinical development, which of course is the primary objective of the entire Sanofi-Synthorx program—to hit …
WebOct 28, 2024 · Sanofi has been working on this IL-2 candidate since 2024 when it acquired San Diego-based Synthorx for a value of $2.5 billion. The deal gave Sanofi control over … pronto by giada menuWebDec 13, 2024 · The addition of THOR-707 and Synthorx’s other earlier-stage cytokine programmes to Sanofi’s pipeline will enhance Sanofi’s position in oncology and in immuno-oncology, the company said.. Synthorx’s Expanded Genetic Alphabet platform is expected to be a source for developing a differentiated therapeutic pipeline. pronto charityWebNov 9, 2024 · THOR-707, SAR444245: IL-2 mutein with P65 replaced by an azide-containing non-natural amino acid, ... (41, 42), CT-ID: NCT04009681: Sanofi: Results: Six phase 1 to 2 … lace leather cropped glovesWebApr 9, 2024 · Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2. April 9, 2024, 4:01 AM UTC. Share this … lace leatherWebApr 18, 2024 · Sanofi unveils data from first-in-human trial for THOR-707. Sanofi was in focus with its interim data from THOR-707 (SAR444245), a not-alpha interleukin-2 (IL-2) candidate. pronto catering perthWebApr 12, 2024 · Since 2024, Merck and Sanofi have each spent billions of dollars on biotechs — Pandion Therapeutics and Synthorx, respectively — with IL-2 treatments in … pronto catheterWebOct 29, 2024 · In addition to testing THOR-707 in combination with KEYTRUDA, Sanofi is separately evaluating the activity of this novel biologic in combination with other anti-PD-1 … pronto catheter thrombectomy